Back
ESC2025 Premium Access

A significant gap remains in LDL-C targets despite the high prescription rate of oral intensive lipid-lowering therapy in post-ACS: there is a need for more widespread usage of PCSK9 inhibitors

Session: New perspectives in cardiology (3) - Risk factors and prevention
Topic: Drug therapy
Speaker: Professor L. Rallidis (Athens, GR)
Event: ESC Congress 2025

Congress Presentation

Add to my library

Like

About the speaker

Professor Loukianos Rallidis

Attikon University Hospital, Athens (Greece)
0 follower

7 more presentations in this session

Discussant - Risk factors and prevention

Access
Like
Thumbnail

Inclisiran: a breakthrough in LDL-C reduction for indian ASCVD patients

Speaker: Doctor R. Yalamanchi (Chennai, IN)

Access
Abstract
Video
Like
Thumbnail

Adherence to statin therapy after inclisiran start, insights from the the DAMAGE registry

Speaker: Associate Professor F. Guerra (Ancona, IT)

Access
Abstract
Video
Like
Thumbnail

Short-term impact of e-cigarrette without nicotine in cardiovascular system in comparison to e-cigarette without nicotine and combustile cigarette

Speaker: Doctor P. Sobieraj (Warsaw, PL)

Access
Abstract
Like
Thumbnail

Disparities in importance physicians place on anti-obesity medications to help prevent cardiovascular comorbidities across the US and Germany

Speaker: Doctor M. Tan (London, GB)

Access
Abstract
Video
Like
Thumbnail

Access the full session

New perspectives in cardiology (3) - Risk factors and prevention

Speakers: Professor L. Rallidis, Doctor R. Yalamanchi, Associate Professor F. Guerra, Doctor P. Sobieraj, Doctor M. Tan
Access
Like
Thumbnail

About the event

Image

ESC Congress 2025

29 August - 1 September 2025

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

bristol-myers-squibb Explore sponsored resources
novartis Explore sponsored resources
novo-nordisk Explore sponsored resources